However, ezrin overexpression failed to predict poor EFS in osteosarcoma (HR 1.20, 95% CI: 0.74–1.96, P = 0.46, PFDR = 1.38, random‐effects; Table 2), which might have been caused by the limited number studies used and indicates the presence of obvious heterogeneity. This evidence concerns the gene EZR and osteosarcoma.